Affiliation:
1. Public Health Research Institute, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey
2. Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania
Abstract
ABSTRACT
Candida parapsilosis
has emerged as a common cause of invasive fungal infection, especially in Latin America and in the neonatal setting.
C. parapsilosis
is part of a closely related group of organisms that includes the species
Candida orthopsilosis
and
Candida metapsilosis
. All three species show elevated MICs for the new echinocandin class drugs caspofungin, micafungin, and anidulafungin relative to other
Candida
species. Despite potential impacts on therapy, the mechanism behind this reduced echinocandin susceptibility has not been determined. In this report, we investigated the role of a naturally occurring Pro-to-Ala substitution at amino acid position 660 (P660A), immediately distal to the highly conserved hot spot 1 region of Fks1p, in the reduced-echinocandin-susceptibility phenotype. Kinetic inhibition studies demonstrated that glucan synthase from the
C. parapsilosis
group was 1 to 2 logs less sensitive to echinocandin drugs than the reference enzyme from
C. albicans
. Furthermore, clinical isolates of
C. albicans
and
C. glabrata
which harbor mutations at this equivalent position also showed comparable 2-log decreases in target enzyme sensitivity, which correlated with increased MICs. These mutations also resulted in 2.4- to 18.8-fold-reduced
V
max
values relative to those for the wild-type enzyme, consistent with kinetic parameters obtained for
C. parapsilosis
group enzymes. Finally, the importance of the P660A substitution for intrinsic resistance was confirmed by engineering an equivalent P647A mutation into Fks1p of
Saccharomyces cerevisiae
. The mutant glucan synthase displayed characteristic 2-log decreases in sensitivity to the echinocandin drugs. Overall, these data firmly indicate that a naturally occurring P660A substitution in Fks1p from the
C. parapsilosis
group accounts for the reduced susceptibility phenotype.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference36 articles.
1. Epidemiology, Risk Factors, and Prognosis of
Candida parapsilosis
Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003
2. Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in
Candida albicans
by Profiling Mutations in
FKS1
3. Bennett, J. E. 2006. Echinocandins for candidemia in adults without neutropenia. N. Engl. J. Med.355:1154-1159.
4. Brito, L. R., T. Guimaraes, M. Nucci, R. C. Rosas, L. Paula Almeida, D. A. Da Matta, and A. L. Colombo. 2006. Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med. Mycol.44:261-266.
5. Cheung, C., Y. Guo, P. Gialanella, and M. Feldmesser. 2006. Development of candidemia on caspofungin therapy: a case report. Infection34:345-348.
Cited by
270 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献